SONO TEK CORP — Form 8-K
Filed October 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Sono-Tek reported first-half FY2027 revenue of $10.89M (up 6% YoY), with gross margin expanding to 55% and operating income up 41% to $1.28M. Medical market sales surged 289% to $7.05M, driven by balloon and stent-coating systems. Post-quarter, the company received $7.19M in orders expected to ship in FY2028. Cash position strengthened to $17.7M with no debt; backlog stands at $9.51M. FY2027 guidance remains flat to modest growth due to timing of large orders, but visibility for FY2028 significantly improved.
Why this rating
Medical growth (+289%) and margin expansion are strong signals; $7.2M FY28 orders (~14% of current market cap) materially boost visibility. Offset by muted full-year FY27 guidance and modest near-term revenue. Meaningful for a $51M company.
See more from October 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.